Literature DB >> 26525925

Food, fibre, bile acids and the pelvic floor: An integrated low risk low cost approach to managing irritable bowel syndrome.

Hamish Philpott1, Sanjay Nandurkar1, John Lubel1, Peter R Gibson1.   

Abstract

Patients presenting with abdominal pain and diarrhea are often labelled as suffering from irritable bowel syndrome, and medications may be used often without success. Advances in the understanding of the causes of the symptoms (including pelvic floor weakness and incontinence, bile salt malabsorption and food intolerance) mean that effective, safe and well tolerated treatments are now available.

Entities:  

Keywords:  Bile acids; Diarrhoea; Food intolerance; Irritable bowel syndrome; Pelvic floor

Mesh:

Substances:

Year:  2015        PMID: 26525925      PMCID: PMC4616214          DOI: 10.3748/wjg.v21.i40.11379

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  42 in total

1.  Prospective comparison of faecal incontinence grading systems.

Authors:  C J Vaizey; E Carapeti; J A Cahill; M A Kamm
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

Review 2.  American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome.

Authors:  Lin Chang; Anthony Lembo; Shahnaz Sultan
Journal:  Gastroenterology       Date:  2014-09-16       Impact factor: 22.682

3.  Treatments of faecal incontinence: recommendations from the French national society of coloproctology.

Authors:  V Vitton; D Soudan; L Siproudhis; L Abramowitz; M Bouvier; J-L Faucheron; A-M Leroi; G Meurette; F Pigot; H Damon
Journal:  Colorectal Dis       Date:  2014-03       Impact factor: 3.788

4.  Perineal retraining improves conservative treatment for faecal incontinence: a multicentre randomized study.

Authors:  Henri Damon; Laurent Siproudhis; Jean-Luc Faucheron; Thierry Piche; Laurent Abramowitz; Marianne Eléouet; Isabelle Etienney; Philippe Godeberge; Guy Valancogne; Angélique Denis; François Mion; Anne-Marie Schott
Journal:  Dig Liver Dis       Date:  2014-01-17       Impact factor: 4.088

Review 5.  Systematic review: the management of chronic diarrhoea due to bile acid malabsorption.

Authors:  C Wilcox; J Turner; J Green
Journal:  Aliment Pharmacol Ther       Date:  2014-03-06       Impact factor: 8.171

6.  Effects of cholestyramine on vitamin E levels in patients treated with statins.

Authors:  F Kersting; A Selenka; S Walch
Journal:  J Clin Pharmacol       Date:  2000-12       Impact factor: 3.126

7.  Chenodeoxycholate in females with irritable bowel syndrome-constipation: a pharmacodynamic and pharmacogenetic analysis.

Authors:  Archana S Rao; Banny S Wong; Michael Camilleri; Suwebatu T Odunsi-Shiyanbade; Sanna McKinzie; Michael Ryks; Duane Burton; Paula Carlson; Jesse Lamsam; Ravinder Singh; Alan R Zinsmeister
Journal:  Gastroenterology       Date:  2010-08-04       Impact factor: 22.682

8.  Characterization of Adults With a Self-Diagnosis of Nonceliac Gluten Sensitivity.

Authors:  Jessica R Biesiekierski; Evan D Newnham; Susan J Shepherd; Jane G Muir; Peter R Gibson
Journal:  Nutr Clin Pract       Date:  2014-04-16       Impact factor: 3.080

9.  Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry.

Authors:  M Camilleri; A Nadeau; W J Tremaine; J Lamsam; D Burton; S Odunsi; S Sweetser; R Singh
Journal:  Neurogastroenterol Motil       Date:  2009-03-13       Impact factor: 3.598

10.  Prevalence of functional bowel disorders and faecal incontinence: an Australian primary care survey.

Authors:  K-S Ng; N Nassar; K Hamd; A Nagarajah; M A Gladman
Journal:  Colorectal Dis       Date:  2015-02       Impact factor: 3.788

View more
  1 in total

1.  Dietary fiber in irritable bowel syndrome (Review).

Authors:  Magdy El-Salhy; Synne Otterasen Ystad; Tarek Mazzawi; Doris Gundersen
Journal:  Int J Mol Med       Date:  2017-07-19       Impact factor: 4.101

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.